Janux Therapeutics
Stock Forecast, Prediction & Price Target
Janux Therapeutics (JANX) stock Price Target by analysts
$79.67
Potential upside: 222.66%
Janux Therapeutics price prediction
What is Janux Therapeutics stock analysts` prediction?
Janux Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Janux Therapeutics in the last 3 months, the avarage price target is $79.67, with a high forecast of $NaN. The average price target represents a 222.66% change from the last price of $24.69.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Janux Therapeutics stock Price Target by analysts
Full breakdown of analysts given Janux Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Justin Zelin BTIG | 0% 0/1 | 9 months ago | $100 305.02% upside | $40.18 | StreetInsider | Previous targets (0) |
David Dai UBS | 0% 0/1 | 11 months ago | $69 179.46% upside | $51.75 | StreetInsider | Previous targets (0) |
Bradley Canino Stifel Nicolaus | 0% 0/1 | about 1 year ago | $70 183.51% upside | $43.71 | StreetInsider | Previous targets (0) |
George Farmer Scotiabank | 0% 0/2 | about 1 year ago | $42 70.10% upside | $36.49 | StreetInsider | Previous targets (1) |
George Farmer Scotiabank | 0% 0/2 | over 1 year ago | $47 90.36% upside | $47.6 | TheFly | Previous targets (1) |
Swayampakula Ramakanth H.C. Wainwright | 0% 0/1 | over 1 year ago | $63 155.16% upside | $49.63 | StreetInsider | Previous targets (0) |
Kaveri Pohlman BTIG | 100% 1/1 | over 1 year ago | $62 151.11% upside | $39.13 | StreetInsider | Previous targets (0) |
Janux Therapeutics Financial Estimates
Janux Therapeutics Revenue Estimates
Janux Therapeutics EBITDA Estimates
Janux Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $3.63M N/A | $8.61M 136.78% | $8.08M -6.14% | Avg: $2.73M Low: $1.17M High: $5.37M avg. -66.18% | Avg: $10.12M Low: $4.34M High: $19.92M avg. 270.55% | Avg: $11.40M Low: $4.88M High: $22.43M avg. 12.56% | Avg: $113.64M Low: $48.73M High: $223.59M avg. 896.79% |
Net Income
% change YoY
| $-32.55M N/A | $-54.15M -66.32% | $-58.29M -7.64% | Avg: $-94.86M Low: $-96.39M High: $-40.05M avg. -62.74% | Avg: $-120.94M Low: $-126.32M High: $-56.78M avg. -27.49% | Avg: $-110.04M Low: $-248.43M High: $-28.33M avg. 9.01% | Avg: $-66.84M Low: $-150.90M High: $-17.20M avg. 39.25% |
EBITDA
% change YoY
| $-32.92M N/A | $-67.09M -103.74% | $-71.02M -5.86% | Avg: $-546.66K Low: $-1.07M High: $-234.41K avg. 99.23% | Avg: $-2.02M Low: $-3.98M High: $-868.65K avg. -270.55% | Avg: $-2.28M Low: $-4.48M High: $-977.82K avg. -12.56% | Avg: $-22.72M Low: $-44.71M High: $-9.74M avg. -896.79% |
EPS
% change YoY
| -$0.79 N/A | -$1.31 -65.82% | -$1.32 -0.76% | Avg: -$1.61 Low: -$2.19 High: -$0.91 avg. -21.63% | Avg: -$2.02 Low: -$2.87 High: -$1.29 avg. -26.07% | Avg: -$2.5 Low: -$5.64 High: -$0.64 avg. -23.50% | Avg: -$1.52 Low: -$3.43 High: -$0.39 avg. 39.25% |
Operating Expenses
% change YoY
| $36.56M N/A | $75.70M 107.03% | $81.06M 7.07% | Avg: $5.82M Low: $2.49M High: $11.46M avg. -92.81% | Avg: $21.59M Low: $9.25M High: $42.48M avg. 270.55% | Avg: $24.30M Low: $10.42M High: $47.81M avg. 12.56% | Avg: $242.27M Low: $103.89M High: $476.65M avg. 896.79% |
FAQ
What is Janux Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -10.48% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -96.39M, average is -94.86M and high is -40.05M.
What is Janux Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 278.43% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $1.17M, average is $2.73M and high is $5.37M.
What is Janux Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -7.98% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$2.19, average is -$1.61 and high is $-0.91.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Janux Therapeutics stock. The most successful analyst is Justin Zelin.